Joint Statement following the visit of US Special Presidential Envoy for Climate John Kerry to the European Commission; March . Read the latest statements and press releases from Barclays and announcements about our key campaigns. The acquisition is subject to customary closing conditions, including the receipt of TSX … Press Releases. The complete, corrected release follows: Sojournix is a clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative new medicines for the treatment of women’s health and neuroendocrine disorders. Latest press releases and statements . Today; Last 7 days; Last 30 days; March. To learn more about Sojournix, please visit www.sojournixpharma.com. 10-03-2021 Press release - Just Eat Takeaway.com FY 2020 Results; 02-02-2021 Press Release – Just Eat Takeaway.com successfully raises EUR 1,100 million through an offering of convertible bonds; 01-02-2021 Press Release – Just Eat Takeaway.com announces the launch of an offering of convertible … Cookies are used to offer you a better browsing experience and to analyze our traffic. Sojournix is a clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative new medicines for the treatment of women’s health and neuroendocrine disorders. About Us; Editorial Team ; Exclusive Interviews; In the News ; Partners & Affiliates Tue. TOKYO, August 6, 2019 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced dosing of the first patient in the SKYLIGHT 1™ Phase 3 pivotal trial for fezolinetant, an investigational oral, non-hormonal compound being studied for the treatment of moderate-to-severe vasomotor symptoms (VMS) – i.e., hot flashes and night sweats … About Sojournix. This press release contains forward looking statements within the meaning of that term in the Private Securities Litigation Reform Act of 1995 (Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934). Tags: People News; Alexion; Avrobio; bluebird bio; Entrada Therapeutics; Merck KGaA; Sanofi; Zafgen; Corporate Affairs; Candel Therapeutics Appoints Paul-Peter Tak as CEO; Expands … Article Comments (0) FREE Breaking News … Sojournix, a clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative new medicines for the treatment of womens health and neuroendocrine disorders, announces that Daniel Grau, Chief Executive Officer of Sojournix, will present at the Cowen and Company 40th Annual Health Care Conference on Wednesday, March 4 at 2:30pm ET at the Boston Marriott Copley The company is developing SJX-653, a novel, potent, selective neurokinin 3 (NK3) antagonist, as a non-hormonal once-daily therapy for moderate to severe vasomotor symptoms (commonly called … Page: Sojournix Announces Publication of Results from SJX-653 Proof-of-Mechanism Study in The Journal of Clinical Endocrinology & Metabolism. Sojournix to Present at Evercore ISI 3rd Annual HealthCONx Virtual Conference - Press Release - Digital Journal Email The complete, corrected release follows: By continuing to use our service, you agree to our use of cookies. 09. The company is developing SJX-653, a novel, potent, selective neurokinin 3 (NK3) antagonist as a non-hormonal once-daily therapy for moderate to severe vasomotor symptoms (commonly called … We also use them to share usage information with our … Energy, environment and climate | European Commission. Sojournix Poster Presentation At ENDO 2019 Features Positive Data From SJX-653 Proof-of-Mechanism Clinical Study. In the news release, Sojournix to Present at Stifel 2019 Healthcare Conference, issued 05-Nov-2019 by Sojournix over PR Newswire, we are advised by the company that the conference date in paragraph 1 was incorrect and should read "Wednesday, November 20" rather than "Tuesday, November 9" as originally issued inadvertently. 02/09/2020 Unilever to eliminate fossil fuels in cleaning products by 2030 Press release. The company is developing SJX-653, a novel, potent, selective neurokinin 3 (NK3) antagonist as a non-hormonal once-daily therapy for moderate to severe vasomotor symptoms (commonly called hot … Sojournix is a clinical stage pharmaceutical company focused on creating new medicines to improve the treatment of women's health and neuroendocrine disorders. Press Releases. See press release dated December 17, 2020 for full terms. Sojournix is a clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative new medicines for the treatment of women’s health and neuroendocrine disorders. About . Press Release; mesdopetam; IRLAB; Parkinson's; Internal Medicine; Corporate Affairs; Entrada Therapeutics Strengthens Leadership Team with Key Appointments (Ref: Business Wire) Published: December 8, 2020. Sojournix, a clinical stage biopharmaceutical company focused on developing and commercializing novel therapies for the treatment of women's health and neuroendocrine disorders, today America First Multifamily Investors, L.P. press releases are available at www.ataxfund.com. 09. 01/09/2020 Unilever to acquire Liquid I.V. Sojournix is a clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative new medicines for the treatment of women’s health and neuroendocrine disorders. Forward-looking statements are statements … Sojournix Stock sojournixpharma.com | BioTech | Founded: 2016 | Funding to Date: $71,390,000 Operator of a biotechnology agency intended to offer innovative medicines. Fluor helps clients meet their sustainability goals with a relentless focus on caring for people, communities and the environment. Stockhouse.com use cookies on this site. Fluor's 2019 Sustainability Report highlights how we are making a lasting impact on the world. We are advancing SJX-653, a … Submit Press Release; Tips; QUICK LINKS : Goldman Sachs Conviction Buy List ; Warren Buffett News; Elliott Associates News; Follow @Street_Insider; Business Wire, Press Releases. Sojournix Advances Phase 2 Clinical Trial of SJX 653 for Menopausal Hot Flashes Sojournix is a clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative new medicines for the treatment of women's health and neuroendocrine disorders. Additional written or oral forward looking statements may be made by the Company from time to time in filings with the Securities and … In the news release, Sojournix to Present at Stifel 2019 Healthcare Conference, issued 05-Nov-2019 by Sojournix over PR Newswire, we are advised by the company that the conference date in paragraph 1 was incorrect and should read "Wednesday, November 20" rather than "Tuesday, November 9" as originally issued inadvertently. Press release. This press release may include forward-looking statements that involve risks and uncertainties. In this section we will keep you posted on regulated press releases concerning our company. Tue.